Viral Hemorrhagic Fever
Symptoms, Doctors, Treatments, Advances & More

Viral Hemorrhagic Fever Overview

Save information for later
Sign Up

Learn About Viral Hemorrhagic Fever

What is the definition of Viral Hemorrhagic Fever?
Viral hemorrhagic fevers is a term used to describe a group of illnesses caused by four different families of viruses that severely affect multiple body systems. Some of the more commonly known types of viral hemorrhagic fevers include Ebola virus, Lassa fever, Hantavirus, Tick-borne encephalitis, and Rift Valley fever. Viral hemorrhagic fevers are carried by insects, rats, and mice and are limited to specific geographical areas in which the insects and animals live, such as West Africa (Lassa fever). While humans can be infected by contact with an infected insect or animal, these viruses can also be transmitted from one human to another and are highly contagious.
What are the symptoms of Viral Hemorrhagic Fever?
While certain types of viral hemorrhagic fevers may cause only mild illness, many of these can cause severe, life-threatening symptoms, and even death. Symptoms may also include muscle aches, extreme fatigue, and high fever. An infected person’s vascular system is often damaged, while the body loses ability to regulate. Vascular damage causes hemorrhage (bleeding).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Viral Hemorrhagic Fever?
Most viral hemorrhagic diseases have no treatment. However, the antiviral drug, ribavirin, may help to shorten the course of illness, and, in some cases, may even prevent infection. Patients are mainly treated with supportive care, which includes prevention of dehydration. Some patients may need kidney dialysis in the event of kidney failure.
Who are the top Viral Hemorrhagic Fever Local Doctors?
Elite in Viral Hemorrhagic Fever
Elite in Viral Hemorrhagic Fever
Referral may be required
12 Science Drive 2, 
Singapore, SG 

David Lye practices practicing medicine in Singapore, Singapore. Mr. Lye is rated as an Elite expert by MediFind in the treatment of Viral Hemorrhagic Fever. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Dengue Fever, Viral Hemorrhagic Fever, Methicillin-Resistant Staphylococcus Aureus (MRSA), COVID-19, and Hepato-Pancreato-Biliary Surgery.

Elite in Viral Hemorrhagic Fever
Elite in Viral Hemorrhagic Fever
Referral may be required
Bernhard Nocht Str. 74, 
Hamburg, HH, DE 

Stephan Gunther practices practicing medicine in Hamburg, Germany. Mr. Gunther is rated as an Elite expert by MediFind in the treatment of Viral Hemorrhagic Fever. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Lassa Fever, Viral Hemorrhagic Fever, Ebola Virus Disease, and Marburg Hemorrhagic Fever.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Viral Hemorrhagic Fever
Elite in Viral Hemorrhagic Fever
Referral may be required
Leuven, VLG, BE 

Johan Neyts practices practicing medicine in Leuven, Belgium. Mr. Neyts is rated as an Elite expert by MediFind in the treatment of Viral Hemorrhagic Fever. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Yellow Fever, Hepatitis E, Viral Hemorrhagic Fever, Parainfluenza Virus Type 3, and Lung Transplant.

View All Doctors
What are the latest Viral Hemorrhagic Fever Clinical Trials?
Emetine for Viral Outbreaks: A Phase 2/3 Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Emetine for Dengue Fever (a.k.a. EVOLVE Antiviral Initiative)
Emetine for Viral Outbreaks: A Phase 2/3 Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Emetine for Dengue Fever (a.k.a. EVOLVE Antiviral Initiative)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

Summary: The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma leakage, severe bleeding, or severe organ involvement)? 2. What are the safety outcomes of emetine, incl...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Biological
Study Phase: Phase 3

Summary: The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.

View All Clinical Trials